tbuckley/cabot-search huggingface dataset:
<i>Notes from the Field</i>: Surveillance for <i>Candida auris</i> — Colombia, September 2016–May 2017
Authors: Patricia Escandón, Diego H. Cáceres, Andres Espinosa-Bode, Sandra Rivera, Paige Armstrong, Snigdha Vallabhaneni, Elizabeth L. Berkow, Shawn R. Lockhart, Tom Chiller, Brendan R. Jackson, Carolina Duarte
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

After a 2016 CDC alert describing infections caused by the multidrug-resistant fungus Candida auris (1), the Colombian Instituto Nacional de Salud (INS) queried the country's WHONET † database of invasive Candida isolates to detect previous C. auris infections.No C. auris isolates were identified during 2012-2016.However, C. auris is often misidentified as Candida haemulonii (2), a yeast that rarely causes invasive infections, and 75 C. haemulonii isolates were reported during May 2013-August 2016.These isolates came primarily from patients in intensive care units in the country's north region, approximately 350-600 km (220-375 miles) from Maracaibo, Venezuela, where C. auris cases were first identified in 2012 (3).Of the 75 reported Colombian C. haemulonii isolates in WHONET, INS obtained 45 isolates from six medical institutions dating from February 2015 through August 2016, all of which were confirmed to be C. auris by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry.Based on these findings, INS issued a national alert and mandated reporting of suspected isolates on August 30, 2016 § (3,4).In September 2016, a team from INS, CDC, and medical staff members from hospitals with documented C. auris cases investigated the 45 MALDI-TOF-confirmed C. auris cases identified before the INS alert.This investigation involved two hospitals in the north region and two in the central region.Cases were clustered within specific hospital units, and surveillance sampling demonstrated transmission in health care settings (INS and CDC, unpublished data, 2018).After release of the Colombian clinical alert, INS received suspected C. auris isolates for confirmatory testing, and during September 2016-May 2017, an additional 78 C. auris cases were identified from 24 health care facilities in nine states, resulting in a total of 123 confirmed C. auris cases (Figure), more than half (54.5%) recovered from the northern coastal * These authors contributed equally.
Author Correction: Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis
Authors: Francesc Coll, Jody Phelan, Grant A. Hill-Cawthorne, Mridul B. Nair, Kim Mallard, Shahjahan Ali, Abdallah M. Abdallah, Saad Alghamdi, Mona Alsomali, Abdallah O. Ahmed, Stephanie Portelli, Yaa Oppong, Adriana Alves, Theolis Barbosa Bessa, Susana Campino, Maxine Caws, Anirvan Chatterjee, Amelia C. Crampin, Keertan Dheda, Nicholas Furnham, Judith R. Glynn, Louis Grandjean, Dang Minh Ha, Rumina Hasan, Zahra Hasan, Martin L. Hibberd, Moses Joloba, Edward C. Jones-López, Tomoshige Matsumoto, Anabela Miranda, David J. Moore, Nora Mocillo, Stefan Panaiotov, Julian Parkhill, Carlos Penha, João Perdigão, Isabel Portugal, Zineb Rchiad, Jaime Robledo, Patricia Sheen, Nashwa Talaat Shesha, Frik A. Sirgel, Christophe Sola, Erivelton Oliveira Sousa, Elizabeth M. Streicher, Paul Van Helden, Miguel Viveiros, Robert M. Warren, Ruth McNerney, Arnab Pain, Taane G. Clark
Journal: Nature Genetics (2018)
TCTAP A-100 Polymer-free Versus Biodegradable Polymer Drug-eluting Stents for the Treatment of Coronary Artery Disease: A Meta-analysis of Randomized Trials
Authors: Sean Tan, Jason Nogic, Paul Thein, Nitesh Nerlekar, James Cameron, Arthur Nasis, Nick West, Adam Brown
Journal: Journal of the American College of Cardiology (2018)
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Authors: Nancy Reau, Paul Y. Kwo, Susan Rhee, Robert S. Brown, Kosh Agarwal, Peter Angus, Edward Gane, Jia‐Horng Kao, Parvez S. Mantry, David Mutimer, K. Rajender Reddy, Tram T. Tran, Yiran B. Hu, Abhishek Gulati, Preethi Krishnan, Emily O. Dumas, Ariel Porcalla, Nancy S. Shulman, Wei Liu, Suvajit Samanta, Roger Trinh, Xavier Forns
Journal: Hepatology (2018)

Well-tolerated, ribavirin-free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority. Once-daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks posttreatment (SVR12) across all major HCV genotypes (GTs). This trial evaluated the safety and efficacy of glecaprevir/pibrentasvir for patients with chronic HCV GT1-6 infection who had received a liver or kidney transplant. MAGELLAN-2 was a phase 3, open-label trial conducted in patients who were ≥3 months posttransplant. Patients without cirrhosis who were HCV treatment-naive (GT1-6) or treatment-experienced (GT1, 2, 4-6; with interferon-based therapy with or without sofosbuvir, or sofosbuvir plus ribavirin) received glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks. The primary endpoint compared the percentage of patients receiving glecaprevir/pibrentasvir with SVR12 to a historic SVR12 rate based on the standard of care. Safety of glecaprevir/pibrentasvir was assessed. In total, 80 liver transplant and 20 kidney transplant patients participated in the trial. Most patients had no or minimal fibrosis (80% had fibrosis scores F0-F1) and were infected with HCV GT1 (57%) or GT3 (24%). The overall SVR12 was 98% (n/N = 98/100; 95% confidence interval, 95.3%-100%), which exceeded the prespecified historic standard-of-care SVR12 threshold of 94%. One patient experienced virologic failure. One patient discontinued because of an adverse event considered to be unrelated to treatment; this patient achieved SVR12. Adverse events were mostly mild in severity, and laboratory abnormalities were infrequent.Once-daily glecaprevir/pibrentasvir for 12 weeks is a well-tolerated and efficacious, ribavirin-free treatment for patients with chronic HCV GT1-6 infection who have received a liver or kidney transplant. (ClinicalTrials.gov NCT02692703.) (Hepatology 2018; 00:000-000).
External validation of clinical scoring system for the prediction of hepatocellular carcinoma in chronic hepatitis B treated by nucleotide/nucleoside analogue
Authors: M. Kurosaki, J. Itakura, T. Nobuharu, Y. Yasui, K. Tsuchiya, H. Nakanishi, K. Takaura, N. Izumi
Journal: Journal of Hepatology (2018)
TCTAP A-119 Trans-ulnar Coronary Angiogram (CAG) and Percutaneous Coronary Intervention (PCI) Is a Safe and Effective Alternative Route than Conventional Trans-femoral and Trans-radial Route-our Experiences at Apollo Hospitals Dhaka
Authors: Ahm Waliul Islam, Shams Munwar, Azfar H. Bhuiyan, Shahab Uddin Talukder, A.Q.M. Reza, Tamzeed Ahmed, Nighat Islam, Atique Siddique, Intekhab Yousuf, Aparajita Karim, M.S. Alam
Journal: Journal of the American College of Cardiology (2018)
Abstract 14225: The Impact of Family History of Premature Cerebrocardiovascular Disease or Diabetes Mellitus on the Occurrence of Gestational Hypertensive Disease and Diabetes
Authors: Chang-hwan Yoon, In-Ho Chae, Dong-ju Choi
Journal: Circulation (2016)

Introduction:  Gestational hypertensive diseases (GHD) and gestational diabetes mellitus (GDM) are well-known to increase the risk of cerebrocardiovascular diseases (CCVD) later in life. However, the association between gestational diseases and the familial history of CCVD has not been investigated yet.   Hypothesis:  Family history of CCVD may be a predictor of GHD or GDM.   Methods:  The Korean Nurses’ Survey was conducted through web-based computer-assisted self-interview, which was compiled by consultation to cardiologists, gynecologists, and statisticians. We enrolled a total of 9,989 female registered nurses who could answer reliably the questionnaires including the family history of premature CCVD (FHCVD), hypertension (FHH), diabetes mellitus (FHDM) based on their medical knowledge. Either multivariate logistic regression analysis or generalized estimation equation was used to clarify the effect of the family histories on GHD and GDM in individual subjects or at each repeated pregnancy in an individual.   Results:  In this survey, 3,695 subjects had more than 1 pregnancy and 8,783 accumulative pregnancies. Among them, 247 interviewees (6.3%) experienced GHD and 120 (3.1%) experienced GDM. In a multivariate analysis adjusting the family histories, obstetric and gynecologic variables, the age at the first pregnancy more than 35 years (adjusted OR 1.61, 95% CI 1.02 - 2.43,  p  = 0.030) and FHCVD (adjusted OR 1.60, 95% CI 1.16 - 2.22,  p  = 0.004) were significant factors for GHD in individuals whereas FHH was not. FHDM and a history of infertility therapy were significant risk factors for GDM in individuals (adjusted OR 2.68, 95% CI 1.86 - 3.86,  p   p  = 0.079). In any repeated pregnancies in an individual, age at the pregnancy, the first pregnancy and FHCVD were significant risk factors for GHD while age at the pregnancy, history of infertility therapy and FHDM were significant risk factors for GDM.   Conclusions:  The FHCVD or FHDM is significantly associated with GHD or GDM, respectively. Meticulous family history should be taken and then special monitoring should be performed for the women with the family histories during pregnancy.
Non-selective beta-blockers reduce cardiac systolic function and impair renal function in patients with refractory ascites
Authors: L. Téllez, L. Ibañez, C.P. del Villar, E. Rodríguez-Santiago, R. Yotti, J. Martinez, M.Á. Rodríguez-Gandía, L. Carrión, M. Rivera, J. Bermejo, F. Gea, R. Bañares, A. Albillos
Journal: Journal of Hepatology (2018)
Effects of <scp>HLA</scp>–B27 on Gut Microbiota in Experimental Spondyloarthritis Implicate an Ecological Model of Dysbiosis
Authors: Tejpal Gill, Mark Asquith, Stephen R. Brooks, James T. Rosenbaum, Robert A. Colbert
Journal: Arthritis & Rheumatology (2017)

To investigate whether HLA-B27-mediated experimental spondyloarthritis (SpA) is associated with a common gut microbial signature, in order to identify potential drivers of pathogenesis.The effects of HLA-B27 on 3 genetic backgrounds, dark agouti (DA), Lewis, and Fischer, were compared, using wild-type littermates and HLA-B7-transgenic Lewis rats as controls. Cecum and colon tissue specimens or contents were collected from the rats at 2, 3-4, and 6-8 months of age, and histologic analysis was performed to assess inflammation, RNA sequencing was used to determine gene expression differences, and 16S ribosomal RNA gene sequencing was used to determine microbiota differences.Both HLA-B27-transgenic Lewis rats and HLA-B27-transgenic Fischer rats developed gut inflammation, while DA rats were resistant to the effects of HLA-B27, and HLA-B7-transgenic rats were not affected. Immune dysregulation was similar in affected Lewis and Fischer rats and was dominated by activation of interleukin-23 (IL-23)/IL-17, interferon, tumor necrosis factor, and IL-1 cytokines and pathways in the colon and cecum, while DA rats exhibited low-level cytokine dysregulation without inflammation. Gut microbial changes in HLA-B27-transgenic rats were strikingly divergent on the 3 different host genetic backgrounds, including different patterns of dysbiosis in HLA-B27-transgenic Lewis and HLA-B27-transgenic Fischer rat strains, with some overlap. Interestingly, DA rats lacked segmented filamentous bacteria that promote CD4+ Th17 cell development, which may explain their resistance to disease.The effects of HLA-B27 on gut microbiota and dysbiosis in SpA are highly dependent on the host genetic background and/or environment, despite convergence of dysregulated immune pathways. These results implicate an ecological model of dysbiosis, with the effects of multiple microbes contributing to the aberrant immune response, rather than a single or small number of microbes driving pathogenesis.
Lung Dendritic Cells Drive Natural Killer Cytotoxicity in Chronic Obstructive Pulmonary Disease via IL-15Rα
Authors: Donna K. Finch, Valerie R. Stolberg, John Ferguson, Henrih Alikaj, Mohamed R. Kady, Bradley W. Richmond, Vasiliy V. Polosukhin, Timothy S. Blackwell, Lisa McCloskey, Jeffrey L. Curtis, Christine M. Freeman
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Lung natural killer cells (NKs) kill a greater percentage of autologous lung parenchymal cells in chronic obstructive pulmonary disease (COPD) than in nonobstructed smokers. To become cytotoxic, NKs require priming, typically by dendritic cells (DCs), but whether priming occurs in the lungs in COPD is unknown.
Comparison of HepaFat-Scan and controlled attenuation parameter for the estimation of hepatic steatosis in patients with non-alcoholic fatty liver disease using histology as the reference standard
Authors: S.H. Menon, L.L. Lai, W.-K. Chan, N.R.N. Mustapha, A. Vijayananthan, S. Mahadeva
Journal: Journal of Hepatology (2018)
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Authors: Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini, Jun Zhou, Michael Manos, Lauren M. Eastman, Holden T. Maecker, F. Stephen Hodi
Journal: Journal for ImmunoTherapy of Cancer (2018)

While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy. To date, most biomarkers of response have been identified in the tumors themselves. Biomarkers that could be assessed from peripheral blood would be even more desirable, because of ease of access and reproducibility of sampling.
Ascites NK cells are phenotypically distinct from blood and liver NK cells in patients with liver cirrhosis and become activated by bacterial stimulation in-vitro and during spontaneous bacterial peritonitis
Authors: P. Lutz, H.C. Jeffery, N. Jones, B. Krämer, J. Birtwistle, J. Nattermann, U. Spengler, C.P. Strassburg, D. Adams, Y.H. Oo
Journal: Journal of Hepatology (2018)
Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis
Authors: Yi-Ming Chen, Tsai-Ling Liao, Hsin-Hua Chen, Der-Yuan Chen
Journal: Annals of the Rheumatic Diseases (2018)

Tuberculosis (TB) remains a major public health issue: an estimated 10.4 million people developed TB disease and 1.4 million died from it in 2015.1 TB risk was 2.28-fold greater in patients with rheumatoid arthritis (RA) compared with controls,2 and even higher in those receiving biologic therapy.3 Guidelines have recommended that latent TB infection (LTBI) screening should be performed and prophylactic therapy be initiated if LTBI exists.4 Consequently, completion of LTBI treatment is essential for TB control in such patients.

The long therapeutic period and hepatotoxicity are barriers to completing 9-month daily isoniazid (9H) treatment,5 the standard LTBI therapy. Recently, implementing 3-month once-weekly isoniazid plus rifapentine (3HP) by directly observed therapy effectively prevented TB and increased treatment adherence.6 However, 3HP regimen has not been assessed for treating LTBI in RA.

Among 188 …
The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura
Authors: Aude-Marie Fourmont, Lara Zafrani, Eric Mariotte, Lionel Galicier, Bérangère Joly, Sybille Merceron, Rémi Bertinchamp, Virginie Lemiale, Audrey de Jong, Sandrine Valade, Michael Darmon, Agnès Veyradier, Elie Azoulay
Journal: Intensive Care Medicine (2018)
Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma
Authors: Hiroshi Higuchi, Natsuko Yamakawa, Ken-Ichi Imadome, Takashi Yahata, Ryutaro Kotaki, Jun Ogata, Masatoshi Kakizaki, Koji Fujita, Jun Lu, Kazuaki Yokoyama, Kazuki Okuyama, Ai Sato, Masako Takamatsu, Natsumi Kurosaki, Syakira Mohamad Alba, Azran Azhim, Ryouichi Horie, Toshiki Watanabe, Toshio Kitamura, Kiyoshi Ando, Takao Kashiwagi, Toshimitsu Matsui, Akinao Okamoto, Hiroshi Handa, Masahiko Kuroda, Naoya Nakamura, Ai Kotani
Journal: Blood (2018)
Endophenotypes in psychiatric disease: prospects and challenges
Authors: William G. Iacono
Journal: Genome Medicine (2018)

Endophenotypes, quantitative neurobehavioral traits that index genetic susceptibility for a psychiatric disorder, have been examined in thousands of studies. Nevertheless, they have underexploited potential to provide etiological insights into prognosis, how psychopathology develops, the etiology of comorbidity, and the mechanisms of gene function.
Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan ® M probe. When should we evaluate steatosis with the XL probe?
Authors: T. Broquetas, L. Canillas, M. Puigvehí, R. Fernández, G. Díaz, S. Coll, M.G. Retortillo, N. Cañete, X. Bessa, R.S. Lamoglia, J.A. Carrión
Journal: Journal of Hepatology (2018)
Effect of multiagent chemotherapy and chemoradiotherapy on rates of resection and survival in patients with locally advanced pancreatic cancer: a National Cancer Database Analysis.
Authors: John David, Sungjin Kim, Eric Anderson, Arman Torossian, Simon Lo, Nicholas N. Nissen, Andrew Eugene Hendifar, Richard Tuli
Journal: Journal of Clinical Oncology (2018)

391 Background: The role of multiagent chemotherapy (MAC) has not been prospectively investigated in LAPC and data are extrapolated from randomized trials in patients with metastatic disease. Data regarding the use of chemoradiation (CRT) for LAPC is mixed and similarly there is no prospective data investigating its use after MAC. Herein, we investigate clinical outcomes associated with the use of MAC and CRT. Methods: The National Cancer Database (NCDB) was utilized to identify LAPC patients treated with single agent chemotherapy (SAC), MAC, surgery, and/or CRT. Univariate (UVA) and multivariate (MVA) Cox regression were performed to identify the impact of MAC and CRT on surgical resection and median overall survival (mOS) rates. Results: From 2004-2014, a total of 10139 patients were identified. The median age was 66 years (range 22-90) with median follow up of 49 months (46-52 months); 49.9% were male and 50.1% female. All patients had clinical stage 3/T4 disease irrespective of nodal metastases. All patients who received post-op RT were excluded. Surgical resection was performed in 506 (5%) patients. Median OS rates for patients who received SAC vs. MAC was 9.8 months vs 13.7 months (p &lt; 0.001), respectively. Median OS rates for patients who received SAC/MAC vs. SAC/MAC+CRT was 9.9 months vs. 12.9 months (p &lt; 0.001), respectively. Odds ratio for undergoing surgical resection in patients receiving MAC vs. MAC+RT was not significant. Of the 5% of patients who underwent resection after neoadjuvant therapy, mOS for those who received MAC vs. MAC+RT were 19.4 months and 25.6 months (p = 0.001), respectively. Conclusions: Median OS was improved in patients receiving MAC versus SAC. The use of CRT after chemotherapy led to increased mOS compared to chemotherapy alone. In all patients undergoing surgical resection, the addition of neoadjuvant CRT after MAC led to improved mOS rates. Treatment with MAC followed by CRT should be utilized for all patients with LAPC.
Ostium Secundum Atrial Septal Defect
Authors: R M Lang, R H Marcus
Journal: New England Journal of Medicine (1995)

Figure 1. Transesophageal echocardiography was performed in a 23-year-old patient who presented with exertional dyspnea, fatigue, and palpitations. Cardiac auscultation revealed fixed splitting of the second heart sound and a short mid-diastolic murmur (grade 1/4) in the fourth left intercostal space parasternally. An rSR߰ pattern was present in precordial lead V1 on the electrocardiogram. Doppler studies showed a pulmonary–systemic flow ratio (QP/QS) of 2.3:1. The patient underwent successful surgical closure of the atrial septal defect.
Abstract 17049: Depeptidyl Peptidase-4 Has A Crucial Role In Pulmonary Arterial Smooth Muscle Cell (PASMC) Proliferation Through Interaction Between Activated T Cells And PASMCs
Authors: Susumu Hosokawa, Go Haraguchi, Taku Ishii, Shozaburo Doi, Mitsuaki Isobe
Journal: Circulation (2013)

Background:  Inflammation is very important for pathophysiology of Pulmonary arterial hypertension (PAH). Dipeptidyl peptidase-4 (DPP-4) plays a crucial role for degrading the incretin hormones that regulates insulin secretion. It is also known that DPP-4 has an important role as a co-stimulatory function for T cell activation. In our present study, we investigated the role of DPP-4 in PAH.   Methods:  40 Sprague Dawley rats were given a single cutaneous injection of monocrotaline (MCT). Starting at day 14 after MCT injection, we administered daily a DPP-4 inhibitor alogliptin (M + A group) or vehicle (M group). We examined in  in vivo  and  in vitro  as follows.   Results:  In  in vitro  experiments, 45% of (M + A) group were still alive at day 30 compared to 5% of M group. Alogliptin markedly improved the right ventricular pressure (33 ± 4.1 mmHg in (M + A) group vs 85.9 ± 1.2 mmHg in M group) in cardiac catheterization. Fibroblast growth factor 2 (FGF 2 ) mRNA level decreased in (M + A) group compared to M group. In  in vitro  experiments, alogliptin suppressed pulmonary arterial smooth muscle cell (PASMC) nuclear factor kappa B (NF-kB) p65 translocation into the nucleus in western blot analysis. In lung tissues, CTLA-4 (cytotoxic T lymphocyte antigen 4), LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for herpesvirus entry mediator on T lymphocytes), and CD86 (cluster of Differentiation 86) mRNA levels, all of which were T-cell co-stimulatory molecules, decreased in (M + A) group compared to M group. Immunohistochemistry revealed that the number of CTLA-4 positive T cells attenuated in (M + A) group than in M group. In addition, alogliptin suppressed phosphorylations both extracellular regulated kinase1/2 and phopholipase C, both of which were regulated by CD86, in PASMCs stimulated with FGF 2 .   Conclusion:  Those results suggest that DPP-4 has a crucial role in PASMC proliferation through interaction between activated T cells and PASMCs. DPP-4 inhibitor alogliptin has potential as a new therapeutic tool for PAH.
Evaporative Cooling Hydrogel Packaging for Storing Biologics Outside of the Cold Chain
Authors: Shiran Ferber, Adam M. Behrens, Kevin J. McHugh, Evan M. Rosenberg, Allison R. Linehan, James L. Sugarman, Hapuarachchige Surangi N. Jayawardena, Robert Langer, Ana Jaklenec
Journal: Advanced Healthcare Materials (2018)

Stabilizing thermolabile pharmaceuticals outside of the cold chain has the potential to alleviate some of the logistical and monetary burden of providing health care access in the developing world. Evaporative cooling hydrogel packaging is designed to extend the storage stability of existing pharmaceutical products without the need for reformulation. Hydrogels with high water content and reversible hydrophilicity offer a promising platform for reducing storage temperatures without refrigeration. As a model, poly(N-isopropylacrylamide) is selected as a basis for creating a potentially low cost and easy-to-fabricate hydrogels.
Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study
Authors: E. Corradini, I. Bernardis, P. Dongiovanni, E. Buzzetti, A. Caleffi, L. Artuso, S. Pelusi, E. Tenedini, E. Tagliafico, R. Rametta, A.L. Fracanzani, S. Fargion, A. Pietrangelo, L. Valenti
Journal: Journal of Hepatology (2018)
The faecal microbiome of patients with primary sclerosing cholangitis has a characteristic signature across different geographic regions
Authors: T. Liwinski, F.-A. Heinsen, M.-C. Rühlemann, C. Bang, R. Zenouzi, J.R. Hov, M. Kummen, T.H. Karlsen, W. Lieb, A. Lohse, A. Franke, C. Schramm
Journal: Journal of Hepatology (2018)